Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label Study of ASP1948, Targeting an Immune Modulatory Receptor, in Japanese Patients With Advanced Solid Tumors

NCT04094506 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT04094506
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04094506 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label Study of ASP1948, Targeting an Immune Modulatory Receptor, in Japanese Patients With Advanced Solid Tumors
Lead sponsor
Astellas Pharma Inc
Phase
Phase 1
Overall status
Completed
Start date
October 30, 2019
Completion date
February 2, 2022
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced (unresectable) or metastatic solid tumor malignancies